Fertility Testing for Women — Complete Guide to Every Test

Deciding to have children is one of the most significant decisions in a person's life — and for many women, understanding their reproductive health before or during that journey is equally important. Fertility testing for women has expanded dramatically over the past two decades. Today, a comprehensive evaluation can assess ovarian reserve, uterine anatomy, tubal patency, hormonal balance, genetic carrier status, and thyroid function — giving couples and individuals a clear picture of their fertility landscape.

This guide explains every major fertility test available to women: what it measures, when to order it, how to interpret results, and how each test connects to a broader clinical picture.

When Should You Get Fertility Testing?

The right time to pursue evaluation depends on age, trying-to-conceive history, and individual risk factors.

Standard Timing Guidelines (ASRM / ACOG)

Risk Factors That Justify Immediate Evaluation

• Irregular or absent menstrual cycles (suggesting ovulatory dysfunction)
• Known or suspected endometriosis
• Prior pelvic inflammatory disease (PID) or sexually transmitted infections
• Prior pelvic, uterine, or ovarian surgery
• Two or more pregnancy losses
• Known genetic condition or family history of premature ovarian insufficiency
• Cancer treatment (chemotherapy or pelvic radiation)
• Partner with known male factor infertility
• Use of donor sperm (single individuals or same-sex couples) — evaluate before first attempt

Ovarian Reserve Tests

Ovarian reserve refers to the quantity and quality of a woman's remaining eggs. It is not a perfect predictor of fertility — women with low reserve can still conceive — but it is the most important indicator of how a woman will respond to fertility treatment. Women with very low AMH or AFC may have diminished ovarian reserve, which warrants prompt specialist evaluation.

Anti-Müllerian Hormone (AMH)

AMH is produced by granulosa cells in the small antral follicles of the ovary. Because it is secreted continuously and does not fluctuate significantly with the menstrual cycle, AMH can be drawn on any day of the month.

AMH is the single best predictor of ovarian response to IVF stimulation. A low AMH predicts poor response (few eggs retrieved); a high AMH predicts hyperresponse (OHSS risk). It is less accurate as a predictor of natural conception than it is for IVF response.

Day-3 FSH (Follicle-Stimulating Hormone)

FSH is drawn on cycle day 2, 3, or 4. At the beginning of the menstrual cycle, the pituitary releases FSH to stimulate follicle development. As ovarian reserve declines, the ovaries become less responsive, and the pituitary compensates by releasing more FSH — like turning up the volume when the speaker gets quieter.

FSH is cycle-to-cycle variable. A single elevated FSH result is clinically meaningful; a single normal result does not rule out reserve problems — it should be interpreted alongside AMH and AFC.

Day-3 Estradiol (E2)

Drawn at the same time as day-3 FSH. A normal estradiol on day 3 is <80 pg/mL. Elevated estradiol on day 3 may indicate early follicle recruitment — a sign of reduced reserve — and can falsely suppress FSH into the normal range. When day-3 estradiol is elevated, a normal FSH may be misleading.

Trying to Conceive at Home?

Understanding your hormonal profile is a key first step — but home insemination can be an accessible, private path to pregnancy for many individuals and couples.

MakeAMom makes reusable at-home insemination kits in three designs: the CryoBaby for frozen or low-volume sperm, the Impregnator for low-motility sperm, and the BabyMaker for those with sensitivities. All ship discreetly and cost far less than a clinical IUI cycle.

Explore home insemination kits at MakeAMom →

Antral Follicle Count (AFC)

The AFC is performed via transvaginal ultrasound, ideally on cycle day 2–5. The sonographer counts all visible small follicles (2–10 mm) across both ovaries. This count directly reflects the pool of follicles available for recruitment in an IVF cycle.

AFC and AMH are highly correlated and together provide the most accurate picture of ovarian reserve. A discordance between AMH and AFC (e.g., normal AMH but low AFC) should be rechecked on a different cycle day.

Hormonal Panel

Thyroid-Stimulating Hormone (TSH)

Thyroid dysfunction — both hypothyroidism and hyperthyroidism — can impair ovulation, implantation, and early pregnancy maintenance. TSH is the most sensitive screening test for thyroid disorders.

• Normal range for fertility: TSH 0.5–2.5 mIU/L (stricter than the general population range)
• Subclinical hypothyroidism (TSH 2.5–4.0 with normal T4) should be discussed with your physician in the preconception context — many endocrinologists recommend treatment before IVF
• Thyroid peroxidase antibodies (TPO Ab) should be checked if TSH is borderline or if there is a family history of autoimmune thyroid disease

Prolactin

Prolactin is a pituitary hormone that normally rises in pregnancy and nursing to suppress ovulation. Elevated prolactin (hyperprolactinemia) outside of these contexts can cause irregular cycles, anovulation, and infertility.

Common causes of elevated prolactin include antipsychotic medications, antidepressants, hypothyroidism, nipple stimulation, and stress at the time of blood draw. A single mildly elevated result should be confirmed with a repeat sample.

LH (Luteinizing Hormone)

LH is measured on day 3 to assess baseline pituitary function and, in combination with FSH, to help identify PCOS. In PCOS, the LH:FSH ratio is often elevated (>2:1 or 3:1). An LH surge mid-cycle triggers ovulation — tracking the LH surge is central to timing intercourse and insemination.

Total and Free Testosterone, DHEA-S, and Androgens

Women with irregular cycles, acne, or hirsutism should have androgens evaluated as part of a PCOS workup. Elevated androgens can suppress ovulation and indicate adrenal or ovarian androgen excess. Tests typically include:

• Total testosterone
• Free testosterone (or free androgen index)
• DHEA-S (reflects adrenal androgen production)
• 17-hydroxyprogesterone (to rule out non-classic congenital adrenal hyperplasia)

Uterine and Tubal Evaluation

Hysterosalpingography (HSG)

HSG is an X-ray procedure performed in the radiology department (or sometimes clinic). A thin catheter is placed through the cervix, and contrast dye is injected into the uterine cavity. X-ray images track the dye to confirm:

1. The uterine cavity is normal (no polyps, fibroids, or septum)
2. Both fallopian tubes are open (patent) — dye should spill freely from each tube into the pelvic cavity

HSG is the primary test for tubal patency and uterine cavity evaluation when:

• Infertility duration exceeds 6–12 months
• There is a history of PID, ectopic pregnancy, or prior tubal surgery
• Prior C-section (to evaluate for Asherman's syndrome or cesarean scar defect)

Discomfort: HSG causes cramping when dye is injected. Taking ibuprofen 600–800 mg one hour before the procedure significantly reduces discomfort. An antibiotic (typically doxycycline) is often prescribed before and after to reduce infection risk.

Limitation: HSG is a two-dimensional X-ray and cannot detect endometriosis, small surface polyps, or assess ovarian or pelvic anatomy beyond the tubes.

Saline Infusion Sonography (SIS/SHG)

SIS is a uterine cavity evaluation performed under ultrasound guidance. Sterile saline is injected through the cervix while a transvaginal ultrasound shows the expanded uterine cavity in real time. SIS detects:

• Endometrial polyps
• Submucosal fibroids
• Uterine septa or congenital anomalies
• Intrauterine adhesions (Asherman's syndrome)

SIS is generally preferred over HSG for uterine cavity evaluation because it provides real-time imaging without radiation, is better at detecting small polyps, and is less uncomfortable than HSG. However, SIS does not evaluate tubal patency.

Many IVF programs require a normal SIS within 6–12 months of the embryo transfer cycle.

3D Transvaginal Ultrasound

3D ultrasound provides superior imaging of uterine anatomy compared to standard 2D. It is particularly useful for:

• Diagnosing uterine septum vs. bicornuate uterus
• Evaluating subseptate uterine anomalies
• Assessing adenomyosis
• Pre-surgical planning

Hysteroscopy

Diagnostic hysteroscopy involves passing a thin camera directly into the uterine cavity. It is the definitive test for intrauterine pathology — any abnormality seen on SIS or HSG can be directly visualized and often corrected at the same time (operative hysteroscopy). It requires anesthesia and is typically performed in an operating room or procedure suite.

Genetic and Immunological Testing

Genetic Carrier Screening

Expanded carrier screening tests for hundreds of inherited conditions (cystic fibrosis, spinal muscular atrophy, fragile X premutation carrier status, hemoglobinopathies, and more) through a simple blood or saliva sample. ACOG recommends offering expanded carrier screening to all women considering pregnancy.

Results guide decisions about PGT-M (preimplantation genetic testing for monogenic disorders) if both partners are carriers for the same recessive condition.

Karyotype (Chromosomal Analysis)

A standard karyotype is recommended for women with:

• Premature ovarian insufficiency (POI) (<40 years)
• Recurrent pregnancy loss
• History of Turner syndrome features

Abnormal karyotypes (e.g., 45,X mosaicism, Robertsonian translocations) affect reproductive prognosis and PGT-A recommendations.

Thrombophilia Panel

Women with recurrent pregnancy loss may be tested for inherited or acquired clotting abnormalities:

• Factor V Leiden
• Prothrombin gene mutation (G20210A)
• MTHFR mutation
• Antiphospholipid antibody syndrome (anticardiolipin antibodies, lupus anticoagulant, beta-2 glycoprotein I antibodies)

Antiphospholipid antibody syndrome is the most clinically actionable finding — treatment with low-dose aspirin and heparin during pregnancy significantly reduces miscarriage risk.

Autoimmune Panel

In recurrent implantation failure or unexplained infertility, some reproductive endocrinologists order autoimmune markers including ANA, anti-dsDNA, and thyroid antibodies, though the clinical utility of routine autoimmune testing in infertility remains debated.

Complete Fertility Testing Sequence: A Practical Overview

What to Do With Your Results

Fertility testing results are meaningfully interpreted in context — a single abnormal value does not always indicate a problem, and a single normal result does not guarantee fertility. Work with a reproductive endocrinologist to synthesize your complete panel into a personalized care plan.

Key action points:

• AMH <1.0 or AFC <7: Discuss fertility preservation (egg freezing) or expedited treatment
• Day-3 FSH >15: Consult a reproductive endocrinologist promptly; IVF with own eggs may have a limited window
• Abnormal uterine cavity on SIS: Surgical correction before IVF significantly improves outcomes
• Both partners carrier for same condition: Genetic counseling and PGT-M discussion
• Elevated prolactin: Medical treatment before IVF improves cycle outcomes

Frequently Asked Questions

Q: What is the difference between AMH and Day-3 FSH for ovarian reserve assessment? A: AMH is produced continuously by small antral follicles and can be drawn on any day of the menstrual cycle with minimal fluctuation — making it the most stable and preferred ovarian reserve marker. Day-3 FSH rises as ovarian reserve declines because the pituitary compensates with stronger signaling, but it is cycle-to-cycle variable. A single normal FSH does not rule out reserve problems; when interpreted alongside AMH and AFC, the three together provide the most accurate picture of ovarian reserve.

Q: What does an elevated Day-3 estradiol result mean? A: A Day-3 estradiol above 80 pg/mL may indicate early follicle recruitment — a sign of reduced ovarian reserve — and can falsely suppress FSH into the normal range. When Day-3 estradiol is elevated, a normal FSH may be misleading and should not be taken as reassuring. Both values should be interpreted together alongside AMH and AFC.

Q: What is the difference between HSG and saline infusion sonography (SIS)? A: HSG uses X-ray with contrast dye injected through the cervix to evaluate both tubal patency and uterine cavity. SIS uses saline injected under real-time ultrasound guidance to evaluate the uterine cavity in detail. SIS is generally preferred for detecting small endometrial polyps, submucosal fibroids, and adhesions, but it does not assess tubal patency. For a complete evaluation before IVF, both tests are typically needed — HSG for tubes, SIS for the cavity.

Q: At what TSH level should thyroid treatment be considered before IVF? A: The fertility-specific normal range for TSH is 0.5–2.5 mIU/L, which is stricter than the general population reference range. Subclinical hypothyroidism (TSH 2.5–4.0 with normal T4) is actively discussed with physicians in the preconception context, and many endocrinologists recommend treatment before IVF. Thyroid peroxidase antibodies (TPO Ab) should also be checked if TSH is borderline or if there is a family history of autoimmune thyroid disease.

Q: Which fertility test confirms that ovulation actually occurred? A: A midluteal serum progesterone level, drawn approximately on day 21 of a 28-day cycle, is the standard test to confirm ovulation occurred. A level above 3 ng/mL confirms ovulation; levels above 10 ng/mL indicate a good luteal phase. OPK strips detect the LH surge that precedes ovulation but do not confirm that the follicle actually released an egg.

Key Takeaways

• Women under 35 should pursue evaluation after 12 months of trying; over 35 after 6 months; over 38 immediately
• The ovarian reserve panel (AMH + day-3 FSH + AFC) is the foundation of every female fertility evaluation
• TSH and prolactin are frequently overlooked but clinically actionable hormonal tests
• HSG evaluates tubal patency; SIS evaluates uterine cavity — both are needed before IVF
• Genetic carrier screening should be offered to all women considering pregnancy regardless of background

References

1. American Society for Reproductive Medicine (ASRM). Diagnostic evaluation of the infertile female: a committee opinion. Fertil Steril. 2015;103(6):e44–e50.
2. American College of Obstetricians and Gynecologists (ACOG). Committee Opinion No. 762: Prepregnancy counseling. Obstet Gynecol. 2019;133(1):e78–e89.
3. Broer SL, Dolleman M, Opmeer BC, et al. AMH and AFC as predictors of excessive response in controlled ovarian hyperstimulation. Fertil Steril. 2011;95(2):525–532.
4. Practice Committee of the ASRM. Testing and interpreting measures of ovarian reserve: a committee opinion. Fertil Steril. 2020;114(6):1151–1157.

This article is for informational purposes only and does not constitute medical advice. Consult a board-certified reproductive endocrinologist for a complete fertility evaluation.